Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer
April 02 2019 - 8:00AM
Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty
pharmaceutical company committed to being the leader in responsible
pain management, today announced the appointment of Richard
Malamut, M.D., as the company’s first Chief Medical Officer,
effective April 1, 2019. In this newly created role, Dr. Malamut
will lead Collegium’s Clinical, Medical Affairs, Regulatory and
Scientific Affairs functions.
“We are excited to have Rick join the Collegium leadership team.
He brings with him more than 25 years of experience across all
stages of product development, as well as clinical and operational
expertise,” said Joe Ciaffoni, Chief Executive Officer of
Collegium. “We look forward to his contributions, as we leverage
his extensive background in the field of pain medicine to deliver
on our commitment to become the leader in responsible pain
management.”
Most recently, Dr. Malamut served as Chief Medical Officer, Head
of Research and Development and Senior Vice President for Braeburn
Pharmaceuticals, Inc. Prior to that, Dr. Malamut was Chief Medical
Officer at Avanir Pharmaceuticals and was Senior Vice President of
Global Clinical Development at Teva Pharmaceutical Industries Ltd.,
where he was responsible for Pain, Neuropsychiatry and repurposing
and reformulation of existing molecules. His experience also
includes roles of increasing responsibility at Bristol-Myers Squibb
and AstraZeneca.
Dr. Malamut earned his medical degree from Hahnemann University
in Philadelphia and completed both a residency in neurology and a
fellowship in neuromuscular disease. He worked as a board-certified
academic and clinical neurologist for 17 years and has more than 50
publications in the fields of pain medicine, neuromuscular disease,
autonomic disease and neurodegenerative disease.
“My experience in developing medicines for pain management equip
me with a unique perspective to apply to the advancement and
expansion of Collegium’s pain portfolio,” said Dr. Malamut. “I am
thrilled to be joining a company with a deep commitment to offering
differentiated and innovative treatment options for people
suffering from pain and look forward to contributing to the success
of Collegium.”
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company committed to
being the leader in responsible pain management. Collegium’s
headquarters are located in Stoughton, Massachusetts. For more
information, please visit the company’s website at
www.collegiumpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. We may, in some cases, use terms such as "predicts,“
“forecasts,” "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "should" or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Such statements are subject to numerous important
factors, risks and uncertainties that may cause actual events or
results to differ materially from the company's current
expectations. Management's expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
factors, including our ability to obtain and maintain regulatory
approval of our products and product candidates; our ability to
effectively commercialize in-licensed products and manage our
relationships with licensors; the success of competing products
that are or become available; our ability to obtain reimbursement
and third-party payor contracts for our products; the rate and
degree of market acceptance of our products and product candidates;
the outcome of any patent infringement or other litigation that may
be brought by or against us, including litigation with Purdue
Pharma, L.P. and Teva Pharmaceuticals USA, Inc.; our ability to
secure adequate supplies of active pharmaceutical ingredient for
each of our products and product candidates; our ability to comply
with stringent U.S. and foreign government regulation in the
manufacture of pharmaceutical products, including U.S. Drug
Enforcement Agency, or DEA, compliance; and the accuracy of our
estimates regarding expenses, revenue, capital requirements and
need for additional financing. These and other risks are described
under the heading "Risk Factors" in our Annual Report on Form 10-K
for the year ended December 31, 2018, and in other reports which we
file with the SEC. Any forward-looking statements that we make in
this press release speak only as of the date of this press release.
We assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Contact: Alex Dasalla adasalla@collegiumpharma.com
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Collegium Pharmaceutical (NASDAQ:COLL)
Historical Stock Chart
From Apr 2023 to Apr 2024